Hepatitis delta virus (HDV) is a naturally occurring infective agent of humans (53) . HDV as a major health problem leads to chronic liver disease or fulminant hepatitis with rapid progression to death (22, 52) . HDV virions contain a 1.7-kb singlestranded circular RNA genome, HDV-encoded protein (hepatitis delta antigen [HDAg] ), and a surrounding lipid envelope embedded with hepatitis B virus (HBV) surface antigen proteins encoded by the hepadnavirus (1, 36, 47, 52, 66, 67) . It has been clearly demonstrated that HBV provides helper function only for HDV entry and release, as delta genome replication proceeds without HBV gene products (35) .
HDV replicates entirely through RNA intermediates via a rolling-circle mechanism (15) , which is analogous to that proposed for viroids (3) . RNA of genomic polarity found in incoming virions serves as a template for the production of antigenomic RNA, of the opposite polarity (61) . Antigenomic RNA can serve as a template for synthesis of new genomic RNA and is the coding strand for HDAg. In virions, there are two main HDAg proteins, a 195-and 214-amino-acid species (36, 47, (66) (67) (68) . These two proteins are translated from two genetically different HDV RNA species. The large HDAg contains the entire small-antigen open reading frame (ORF) plus 19 additional amino acids at the C terminus (68) . An RNAediting process is required to create the template for subsequent translation of the large-HDAg mRNA (4, 43, 72) . These two isoforms of HDAg have entirely different functions. While the small HDAg is required for genome replication (35) , the large HDAg acts as an inhibitor for replication and is required for HDV assembly (6, 10, 19, 54) . However, the underlying mechanism by which HDAgs affect replication of the viral RNA remains unclear.
Both forms of HDAg have been detected as nuclear phosphoproteins (7, 30) , but the large form is more heavily phosphorylated than the small form when expressed in insect cells (30) . Although the phosphoamino acid analysis indicates that serine is the phosphorylated residue in the large HDAg (7), the exact residue as well as the functional significance of phosphorylation in HDV virion assembly and replication has not yet been determined.
In this study, we have characterized the phosphorylation property of two HDAgs in a human hepatoma cell line and investigated the functional role of HDAg phosphorylation in HDV RNA replication, packaging, and nuclear transport. Our results suggest that while phosphorylation of Ser-2 is important for the small HDAg's replication function, phosphorylation of three conservative serine residues (Ser-2, Ser-123, and Ser-210) does not confer any role in the assembly of the empty viral particle, or in the large HDAg's trans-dominant inhibitory effect on HDV replication. Furthermore, phosphorylation is not a prerequisite for entrance of either form of HDAg into the nucleus. To our knowledge, this is the first report regarding the phosphorylation and function of HDAg.
MATERIALS AND METHODS
Plasmids. The HDV sequence used in this study was derived from plasmid pSVLD3 (35) . Plasmid pSVL-d2g, a derivative of mammalian cell expression vector pSVL (Pharmacia), contains a head-to-tail tandem dimer of the fulllength HDV cDNA (as a 1.7-kb XbaI fragment) inserted at the XbaI site of the vector plasmid pSVL in the genomic orientation with respect to the simian virus 40 late promoter. On transfection into HuH-7 cells, the plasmid can direct replication of the viral genome and expression of the two species of HDAg. HDV virions are produced upon cotransfection with an HBV surface antigen (HBsAg) expression construct (69) . Plasmid pSVLDm2 contains a tandem dimer of the full-length, mutated HDV cDNA in which the mutation in the large HDAg ORF prevents expression of the large HDAg but not the small HDAg (6) . Plasmid pCDm2G contains a tandem dimer of the full-length, mutated HDV cDNA in which a frameshift mutation in the HDAg ORF destroys the production of both large and small HDAgs (64) and requires the functional small HDAg in trans for replication. Plasmid pGEM3L, a derivative of pGEM-3Zf(Ϫ) (Promega), contains a ScaI-EcoRI fragment (1.1 kb) of the HDV cDNA driven by the SP6 or the T7 phage promoter (24) . This plasmid allows production of strand-specific probes by in vitro transcription. Plasmid pMTS, a deletion derivative of HBV plasmid pMH9/3091 (32), contains the major HBsAg gene under control of the metallothionein promoter. This plasmid was constructed by deletion of the 1.6-kb SalI-XhoI fragment (spanning core, pre-S1, and pre-S2 regions) from pMH9/3091 and was used in the transfection experiment to provide HBsAg (57) .
Site-directed mutagenesis of the HDAg gene. The Altered Sites system (Promega) was used for in vitro mutagenesis of the HDAg gene as described by the manufacturer. The 1.7-kb XbaI fragment containing the full-length HDV genome was removed from pSVLD3 (35) and subcloned into the XbaI site of pSELECT-1. The resulting construct, pSLC-d, was used for site-directed mutagenesis. The oligonucleotides used for mutation were synthesized and named according to the position of the mutated amino acid in the HDAg and the nature of the amino acids before and after the mutation (see below). Underlining indicates mutated bases. All mutant sequences were confirmed by sequencing. The 1.7-kb XbaI fragment of mutant DNAs in the four pSLC-d derivatives (designated pSLC-d2A, pSLC-d4A, pSLC-d123A, and pSLC-d210A, respectively) was then subcloned into the XbaI site of the pSVL expression vector (Pharmacia) to generate a series of pSVL-d2g mutant derivatives [designated pSVL-d2g(2A), pSVL-d2g(4A), pSVL-d2g(123A), and pSVL-d2g(210A), respectively] containing a tandem dimer of mutated HDV cDNA, which can direct the production of a genomic strand of HDV RNA. On transfection to HuH-7 cells, these pSVL-d2g derivatives presumably can direct replication of the viral genome and expression of the two species of mutant HDAgs. The oligonucleotides were as follows: Ser-2/Ala, 5Ј-CTAGCCGAGATGGCCCGGTCCGAGT CG-3Ј; Ser-4/Ala, 5Ј-GATGAGCCGGGCCGAGTCGAAGTC-3Ј; Ser-123/Ala, 5Ј-CTCTAGCCGAGATGGCCCGGGCCGAGTCGAGGAAGAAC-3Ј; Ser-210/Ala, 5Ј-CTTTTCTCCCCAGGCTTGTCGACCCCAGTG-3Ј.
Construction of the HDAg expression vectors. To construct a plasmid expressing the wild-type or mutated small HDAg defective in the casein kinase II (CKII) or protein kinase C (PKC) recognition site, the 1.1-kb XbaI-BglII fragment containing the ORF of the small HDAg was excised from pSLC-d or its mutant derivatives (pSLC-d2A, pSLC-d4A, and pSLC-d123A) and inserted into the XbaI-BglII-digested vector pECE (16) . The resulting constructs were designated pECE-d, pECE-d2A, pECE-d4A, and pECE-d123A, respectively. To construct a plasmid encoding the ORF of the wild-type large HDAg or the mutated large HDAg defective in the CKII or PKC recognition site, both the designed primer (see above) harboring the mutation within the CKII or PKC recognition site and primer D (5Ј-GGATTTCCATGGGATATACTCTTCC-3Ј), carrying the mutation that converts the termination codon (TAG) of the small HDAg into the tryptophan codon (TGG), were used for site-directed mutagenesis on the template pSLC-d. Only double mutation, where one mutation occurred at the termination codon of the small HDAg and the other mutation occurred at either one of the kinase recognition sites, was selected. The resulting construct was designated pSLC-D, and its mutant derivatives were designated pSLC-D2A, pSLC-D4A, pSLC-D123A, and pSLC-D210A. The 1.1-kb XbaI-BglII fragment encoding the large HDAg was excised from pSLC-D or its mutant derivatives and inserted into the XbaI-BglII-digested vector pECE. The resulting constructs were designated pECE-D, pECE-D2A, pECE-D4A, pECE-D123A, and pECE-D210A, respectively.
Cell culture and transfection. A human hepatoma cell line, HuH-7 (49), was used in all DNA transfection experiments done in this study. Cells were seeded (5 ϫ 10 6 /15-cm-diameter dish) and cultured at 37ЊC under 5% CO 2 for 20 h in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 IU of penicillin per ml, 100 g of streptomycin per ml, and 2 mM L-glutamine. Cells were cotransfected with appropriate amounts of plasmid combinations (40 to 45 g/15-cm-diameter dish) by a calcium phosphate coprecipitation method (20) . The medium was changed after 20 h of incubation with DNA and subsequently replaced and collected at 3-day intervals.
Isolation of HDV particles. The secreted HDV particles were purified according to a method described elsewhere (69) . Briefly, the culture medium collected from transfected cells was clarified by centrifugation at 12,000 rpm in a JA-20 rotor (Beckman) for 30 min. The supernatant was layered over a 20% sucrose cushion and then was centrifuged at 40,000 rpm for 5 h in a Beckman SW41 rotor. The pellets recovered were further processed for HDAg or HDV RNA analysis.
Analysis of HDV and HBV antigens. Culture media of transfected cells were assayed for HBsAg by using enzyme immunoassay kits (General Biologicals Corp., Hsin Chu, Taiwan). For detection of the cellular HDAg, cells were washed twice with phosphate-buffered saline and lysed in Laemmli's buffer (37) . For detection of the HDV antigens in viral particles, the pelleted viral particles from 5 ml of culture medium were dissolved in 200 l of deionized water and 20 l of the dissolved pellet was used to examine the viral antigen in the particles. The protein samples were subjected to electrophoresis through a 12.5% polyacrylamide gel. After being electrotransferred to nitrocellulose paper, the HDAg was detected by immunoblotting with rabbit anti-HDAg sera or human antiHDAg sera as the primary antibody and horseradish peroxidase-conjugated antibody as the secondary antibody. The blot was detected by the enhanced chemiluminescence method (ECL system; Amersham).
Metabolic labeling of phosphorylated HDAg with 32 P i and immunoprecipitation of the HDAg. For labeling the small HDAg, HuH-7 cells (6 ϫ 10 6 ) were cotransfected with expression constructs for the HDV dimeric cDNA (pSVLd2g) (20 g ) and HBsAg gene (pMTS) (20 g). On day 5 posttransfection, cells were treated with 100 M CKII or PKC inhibitor, DRB or H7 (Sigma), respectively, for 24 h or left untreated. The cells were washed twice with phosphate-free medium, starved of phosphate in the same medium for 2 h, and subsequently labeled with 32 P i (0.3 mCi/ml; code no. PBS13; Amersham) in 3 ml of phosphatefree medium with or without the kinase inhibitor. After 4 h of labeling, cells were washed free of labeled medium and processed for immunoprecipitation. For labeling the large HDAg, HuH-7 cells (7 ϫ 10 6 ) were transfected with the expression plasmid pECE-D (40 g) and after 32 h posttransfection cells were treated with kinase inhibitor or left untreated and processed for 32 P i labeling of the HDAg as described above, except that the inhibitor treatment was carried out for 6 h.
For immunoprecipitation, the cells were lysed in 1.2 ml of NET buffer (50 mM Tris-HCl [pH 7.9], 150 mM NaCl, 0.5 mM EDTA, and 0.5% Nonidet P-40) containing protease inhibitors, Complete (Boehringer Mannheim), and phosphatase inhibitors, sodium orthovanadate (10 mM) and sodium fluoride (50 mM). The total lysates were briefly centrifuged to remove cell debris and then immunoprecipitated with protein A-Sepharose 4B-bound human anti-HDAg antibody. Proteins were extracted from the Sepharose 4B beads by the addition of Laemmli's loading buffer (37) and heating at 95ЊC for 5 min. One half of the aliquots of protein samples was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography, and another half was used for Western blot (immunoblot) analysis and probed for HDAg by using rabbit anti-HDAg antibody and the ECL system for detection.
RNA preparation and Northern blotting. Total cellular RNA was extracted by the Ultraspec RNA method as described by the supplier (Biotecx). For detection of the HDV RNA in virions, the purified viral particles from 5 ml of the culture medium were dissolved overnight in 0.4 ml of lysing buffer (50 mM HEPES [N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid] [pH 7.4], 0.2 M NaCl, 20 mM sodium EDTA, 2% SDS, 0.5 mg of proteinase K, 50 g of yeast tRNA) and then extracted twice with phenol-chloroform and subsequently precipitated with ethanol. The RNA samples (20 g per lane) were assayed by 6% formaldehyde-1.5% agarose gel electrophoresis and Northern (RNA) blot analysis. The strandspecific HDV RNA probes for the detection of genomic or antigenomic HDV RNAs were prepared by in vitro transcription of pGEM3L by using the SP6/T7 transcription kit (Promega). Prehybridization and hybridization were performed as described before (62) .
Immunofluorescence. The localization of HDV antigens in transfected cells was observed by immunofluorescence microscopy (58) . Cells were grown on coverslips, fixed with acetone-methanol (Ϫ20ЊC), probed with a human antiHDAg antibody, and then stained with fluorescein isothiocyanate-conjugated goat anti-human immunoglobulin G.
RESULTS

Phosphorylation of HDAgs is affected by CKII and/or PKC inhibitors.
Since phosphorylation of the large HDAg occurs primarily on serine residues (7), it is likely that the same phenomenon may occur on the small HDAg. A comparison of the deduced primary sequences of HDAgs among nine different isolates of HDV revealed that of a total of 7 to 14 serine residues as candidate phosphorylation sites, two putative CKII recognition sites were located at residues Ser-2 and Ser-123 and one potential PKC site was located at Ser-210 in most, if VOL. 70, 1996 PHOSPHORYLATION REGULATES HDV RNA REPLICATION 6191 not all, known HDAg sequences ( Fig. 1 ). Additional PKC sites were found at Ser-4, Ser-6, or Ser-22 in some, but not all, variants of HDAg. The occurrence of these putative CKII or PKC phosphorylation sites in the HDAg suggests that the HDAgs could be the in vivo substrates for these two kinases.
To assess this possibility, an in vivo labeling experiment was performed either with or without the addition of kinase inhibitor (see Materials and Methods). HuH-7 cells were cotransfected with the expression constructs for the HDV dimeric cDNA (pSVL-d2g) and the HBsAg gene (pMTS) to direct HDV RNA replication and virion assembly. Cells were then treated for 24 h on day 5 posttransfection with 100 M DRB or H7, known to block cellular CKII or PKC activity, respectively (33, 56) . HDAgs were metabolically labeled with 32 P i and recovered from the cell lysates by immunoprecipitation. The results of gel electrophoresis and autoradiography showed a highly phosphorylated protein species with the size (24 kDa) expected for the small HDAg ( Fig. 2A , lane 2, position marked S). This phosphorylated protein species presumably represented the small HDAg since it was not detected in the mocktransfection control ( Fig. 2A , compare lane 1 with lane 2) but was recognized by human anti-HDAg specific antibody (Fig.  2B , lane 2). The relative phosphorylation level of this small HDAg species in either CKII inhibitor-or PKC inhibitortreated cells, as analyzed by densitometric scanning, was reduced to about 57 or 45% that of the untreated cells ( Fig. 2A , compare lane 2 with lanes 3 and 4). In contrast, no phosphorylation signal was detected at the expected position (27 kDa) for the large HDAg (Fig. 2A, lane 2 , position marked L). This lack of phosphorylation in the large HDAg may presumably be due to the small protein quantity or low level of phosphorylation of this species relative to that for the small HDAg in the transfected cells (Fig. 2B) . To test these two possibilities, the phosphorylation of the large HDAg was reexamined on HuH-7 cells transfected with the expression construct for the large HDAg (pECE-D) and the transfected cells were treated with the two kinase inhibitors as described earlier (see Materials and Methods). By using this system, the phosphorylation of the large HDAg was detectable, though its intensity was low and required a much longer exposure of the film (Fig. 2C, inhibitor (H7)-treated cells (Fig. 2C , compare lane 2 with lane 4). Note that the results of Western blot analysis showed that the protein levels of all the HDAgs analyzed in these two experiments were apparently the same (Fig. 2B and 2D ). This ensured that the observed reduction in the phosphorylation level did not result from the different amounts of loaded HDAg.
Taken together, these results suggest that in HuH-7 cells the small HDAg is the substrate for both CKII and PKC, while the large HDAg is the substrate only for CKII. This implies that the phosphorylation domains associated with these two HDAgs are rather different. Furthermore, these results also imply that Ser-2 and/or Ser-123 is the potential phosphorylated residue for CKII in these two HDAgs. In contrast, the phosphorylation of the Ser-210 residue by PKC is probably of less importance to the total phosphorylation level of the large HDAg.
Intriguingly, in addition to the phosphorylation signals produced by the small HDAg in the immunoprecipitation experiment, there are some phosphorylation signals that appear for several other protein species (Fig. 2A) . These protein species may result from the coprecipitation of the small HDAg and cellular proteins during the immunoprecipitation. Notably, most of the coprecipitated protein species, all except for the 26-kDa species, were consistently present in other sets of similar experiments. This 26-kDa protein species is not of HDAg origin, because it was not recognized by HDAg-specific antibody. The interactions between the HDAg and these coimmunoprecipitated phosphorylated proteins are rather specific, since in the mock sample without the small HDAg they were either absent or present with much weaker intensity. It is also noted that the phosphorylation intensities of several coimmunoprecipitated protein species may vary between the untreated and the inhibitor-treated cells, suggesting that the extent of phosphorylation of the cellular proteins associated with the HDAg was affected by the protein kinase inhibitors. Alternatively, this could imply that phosphorylation may modulate the interaction between the HDAg and cellular factors.
Inhibitors of both CKII and PKC affect HDV replication. Since the phosphorylation of HDAg could be blocked by the CKII or the PKC inhibitor, it is relevant to know whether this prevention of HDAg phosphorylation also affects HDV replication and assembly. To this end, HuH-7 cells cotransfected with the HDV dimeric cDNA plasmid (pSVL-d2g) and the HBsAg expression construct (pMTS) were treated with a CKII or PKC inhibitor, DRB or H7, respectively, during the period from day 2 to day 6 posttransfection. As shown in Fig. 3A and B, upon treatment with 100 M kinase inhibitor, both the intracellular genomic and the intracellular antigenomic HDV RNAs, as detected by the strand-specific riboprobe, were reduced to 18 to 35% of the levels for transfected cells not treated with inhibitor. Analysis of the secreted virions suggested that both HDAgs and the HDV virion RNA in these inhibitor-treated cells were completely diminished ( Fig. 3D  and E) . Apparently, these two kinase inhibitors significantly inhibited viral replication and assembly. When the intracellular levels of the small HDAg were compared, not much difference between the treated and untreated cells was noted (Fig. 3C) . This shows that the inhibitory effects on HDV RNA replication and assembly achieved by these inhibitors are unlikely to be associated with the reduced production of intracellular small HDAg. However, the intracellular level of the large HDAg was affected by the inhibitors (20 to 40% of control levels) (Fig.  3C) . It is also noted that the effect of the PKC inhibitor in this aspect is more pronounced than that of the CKII inhibitor. The exact cause of the reduction in the level of the large HDAg in these treated cells is not clear (see Discussion). Nevertheless, this may account for the reduced level of virion formation, since the large HDAg is required for the assembly of the HDV particle (6) . Therefore, CKII and PKC are involved in HDV RNA replication; however, their role in HDV virion assembly is unclear, because of the deleterious effects of the inhibitors on the production of the large HDAg.
Inhibitors of both CKII and PKC do not affect the assembly and secretion of the empty HDV particle. To test whether CKII and PKC are involved in the formation or secretion of empty HDV particles, HuH-7 cells cotransfected with the expression constructs for the large HDAg (pECE-D) and HBsAg or with both of these constructs together with the expression construct for the small HDAg (pECE-d) were treated with a CKII or PKC inhibitor. As shown in Fig. 4 , upon treatment with 100 M DRB or H7, HDAgs were detected at the same level in both the intracellular and extracellular fractions of the control and inhibitor-treated cells. This reflects that there was no effect on formation and secretion of the empty HDV particle in the treated cells. Thus, it is unlikely that CKII and PKC are involved in the assembly and secretion of the empty HDV particle.
Mutation at Ser-2 diminishes the activity of the small HDAg in assisting HDV RNA replication. To investigate the effect of phosphorylation on HDAg function, three putative phosphorylated serine residues (Ser-2, Ser-123, and Ser-210), which are conserved in most of the known HDAg sequences and are presumably recognized by these two kinases (Fig. 1) , were replaced by a nonphosphorylatable alanine residue through site-directed mutagenesis (see Materials and Methods). As a control, a mutation was also introduced into Ser-4, which is the putative phosphorylation site recognized by PKC in some isolates of HDAg, but not in the one used for this study (Fig. 1,   FIG. 3 . Effects of kinase inhibitors on HDV replication. HuH-7 cells were cotransfected with equal amounts (20 g each) of HDV dimer plasmid pSVLd2g and HBsAg construct pMTS (lanes 2 to 4). At days 2 to 6 posttransfection, cells were continuously treated with 100 M DRB or H7. Total cellular RNA (A and B) and the RNA of viral particles (E) from cells at day 6 posttransfection were prepared and analyzed by Northern blotting with HDV strand-specific riboprobe (see Materials and Methods). The intensity of HDV RNA (both monomer and dimer forms) was quantified with a phosphorimager and normalized to the intensity of the 18S rRNA in each sample. The intracellular and secreted HDAgs were detected by Western blotting with a human anti-HDAg antibody (see Materials and Methods) (C and D), and the relative band intensity of the large (L) or small (S) form of the HDAg in each sample was quantified with a phosphorimager. Media collected on day 6 posttransfection were also assayed for HBsAg with an enzyme immunoassay kit (see Materials and Methods), and the P/N (sample versus negative control) ratios of HBsAg in treated or untreated cells after proportional normalization at 2 ϫ The mutants harboring the designed mutation were designated S2A, S123A, S210A, and S4A, respectively. To further clarify whether the decrease in HDV genomic replication in the CKII inhibitor-treated cells results from the defect in the replication activity of the small HDAg, the wild type and the mutant form of the small-HDAg expression plasmid (pECE-d and its mutant derivatives) together with plasmid pCDm2G were cotransfected into HuH-7 cells. The construct pCDm2G contains a tandem dimer of the full-length, mutated HDV cDNA harboring a frameshift mutation that prevents the production of both species of HDAg. This plasmid presumably can serve as the template for assay of replication of the HDV genome by being cotransfected with the expression construct for small HDAg (64) . Analysis of the intracellular genomic and antigenomic RNAs in HuH-7 cells at day 6 posttransfection revealed that mutation at Ser-2, but not at Ser-4 and Ser-123, had caused a sevenfold decrease in the replication activity of the small HDAg ( Fig. 5A and B) . Notably, the levels of the wild-type and mutant forms of small HDAg were found to be comparable (Fig. 5C) . Therefore, the integrity of Ser-2, but not that of Ser-123, is important for the activity of the small HDAg in HDV RNA replication.
Ser-2 serves as the phosphorylated site in the small HDAg. From the foregoing study, it is clear that of the two putative CKII recognition sites, Ser-2 but not Ser-123 in the small HDAg plays an important role in HDV replication. To determine if this differential role in HDV RNA replication reflects a distinct phosphorylation property, the levels of phosphorylation contributed by each of the two serine residues were studied. An in vivo labeling experiment indicated that mutation of Ser-2 to Ala in mutant S2A, preventing phosphorylation at that site, led to a decrease (about 35% reduction) in the phosphorylation level in the small HDAg in comparison with the level for the wild type, while no apparent effect was observed for the mutant S123A (Fig. 6 ). This result indicates that Ser-2, rather than Ser-123, serves as the major phosphorylation acceptor site for CKII. This, together with results of the previous experiments ( Fig. 3 and 5) , strongly suggests that the role of CKII in HDV replication is mediated through phosphorylation of Ser-2 but not Ser-123. Additionally, since mutant S2A still shows significant levels of phosphorylation (65%), this indicates that the small HDAg is also phosphorylated on additional residues in vivo.
Notably, a comparison of the phosphorylated proteins coimmunoprecipitated with the wild-type and mutant forms of the small HDAg revealed that an additional phosphorylated species of about 20 kDa was detected only in mutant S2A (Fig. 6) . Although the exact nature of this species is not clear, this result strongly suggests that the phosphorylation at Ser-2 of the small HDAg may regulate its association with other cellular proteins. HDV particle, the large form of HDAg has been shown to have trans-suppressive effects on the replication of the HDV genome (10, 19) . To find out whether phosphorylation may modulate this trans-suppressive activity of the large HDAg, the wild-type or mutant form of the large-HDAg expression construct (pECE-D or its mutant derivatives) together with plasmid pSVLDm2 were cotransfected into HuH-7 cells. The latter construct contains the mutated HDV cDNA in a dimeric form that directs the expression of the wild-type small HDAg but not the large HDAg. As shown in Fig. 7 , when cells were transfected with 20 g of pSVLDm2 and 1/10 the amount (2 g) of the large-HDAg expression construct, all mutant variants of the large HDAg retained their suppressive effects on HDV replication, as demonstrated by the analysis of production of the genomic and antigenomic HDV RNAs (Fig. 7A and  B) . In all cases examined, the amounts of HDAgs expressed were very similar (Fig. 7C) but HDV replication was reduced to 2 to 5% of the level for control cells, not transfected with the large-HDAg expression construct. Thus, phosphorylation of Ser-2, Ser-123, or Ser-210 by these two kinases is not required for the trans-suppressive activity of the large HDAg.
Mutation at Ser-2, Ser-123, or Ser-210 of the HDAgs does not block formation of the empty virus-like particle. In addition to the mature virion, the large HDAg and HBsAg or the large HDAg and HBsAg together with the small HDAg could assemble into the empty virus-like particles (14) . To examine whether phosphorylation of the Ser-2, Ser-123, or Ser-210 residue in these two species of HDAg is required for the formation of the virus-like particle, the wild-type or mutant form of the HDAg expression construct together with the HBsAg expression construct were cotransfected into HuH-7 cells. Analysis of the secreted empty viral particles by immunoblotting indicated that all mutant variants of the large HDAg and the small HDAg retained wild-type ability to form empty viral particles (Fig. 8) . Thus, phosphorylation of HDAg at Ser-2, Ser-123, and Ser-210 by CKII or PKC did not play any role in empty viral particle formation. This result is consistent with the finding obtained from the inhibitor experiment (Fig. 4) and further confirms that PKC and CKII are not involved in the formation of HDV empty virus-like particles.
Mutation at Ser-2, Ser-123, or Ser-210 of the HDAgs does not alter the entrance of HDAg into the nucleus. The HDAg could target to the nuclei of COS cells or hepatoma cells when visualized by indirect immunofluorescence (7, 35, 44) . The subcellular localization of the HDAg mutants was investigated to elucidate whether the mutation in these three putative phosphorylation sites of HDAg might affect the nuclear transport. Our results indicated that all mutant forms of the small or large HDAg retained the ability of the wild type to translocate into the nucleus (data not shown). Therefore, phosphorylation of these three serine residues by CKII or PKC is unlikely to be required for nuclear translocation of the HDAg. Furthermore, the loss of the replication activity of the small HDAg in mutant S2A (Fig. 5) is not accounted for by defective nuclear localization.
DISCUSSION
In this study, we have demonstrated that phosphorylation of HDAg is involved in HDV RNA replication but not in the assembly of the empty viral particle. This is supported by two lines of evidence: (i) when cells were treated with kinase inhibitors to influence the intracellular actions of CKII or PKC, the phosphorylation level of the small HDAg was reduced by the inhibitors and concomitantly affected HDV replication but not empty particle formation (Fig. 2 to 4) ; (ii) results obtained with mutants with alanine substitutions at CKII or PKC recognition sites indicated that mutation at Ser-2 in the small HDAg to prevent phosphorylation at that position appeared to have a much stronger influence on HDV RNA replication than did mutation at any other serine residue tested ( Fig. 5 and 6 ). In contrast, the integrity of Ser-2, Ser-123, or Ser-210 seemed functionally irrelevant to the two unique biological properties of the large HDAg, i.e., the assembly of empty viral particles (Fig. 8 ) and the trans-dominant inhibitory effect on HDV replication (Fig. 7) . Although in this study we have investigated the functional roles in the HDV life cycle of the three most highly conserved serine residues of HDAg, the functional involvement of other putative PKC or CKII sites in the HDAg (e.g., Ser-4, Ser-6, Ser-22, Thr-37, Thr-95, or Thr-134) (Fig. 1 ) cannot be completely excluded. In particular, when considering that the small HDAg has the phosphorylation acceptor site for PKC that presumably is important for the replication activity of the small HDAg ( Fig. 2 and 3) and that the phosphorylated amino acid in this species of HDAg is not yet determined, we can only speculate that the PKC-phosphorylated site may occur on those less conservative serine or threonine residues (e.g., Ser-6, Thr-37, or Thr-95 in variant a) (Fig. 1) . Additionally, these two kinases may participate in HDV replication through their actions on cellular proteins. Support for this view comes from the findings that HDV replication is carried out by the DNAdependent transcriptional complexes composed of the HDAg, the cellular RNA polymerase II (17, 45) , and several transcriptional factors such as c-Jun, SP1, and TATA-binding protein (11) . Conceivably, CKII or PKC enzyme could act in HDV replication in part through modification of these cellular factors. Consistent with this notion are the findings that the subunits of RNA polymerase II are phosphorylated by CKII, that this phosphorylation is accompanied by a stimulation of RNA polymerase activity (59, 63) , and that the transcriptional activity of c-Jun is positively regulated by PKC through the sitespecific dephosphorylation of its DNA-binding domain (2) .
The reduction in production of the intracellular large HDAg but not the small HDAg in the kinase inhibitor-treated cells transfected with HDV dimeric cDNA plasmid (pSVL-d2g) is rather intriguing (Fig. 3C) . Although the exact basis of this phenomenon is unclear, there are several possible explanations. First, the fact that no such reduction in production of HDAgs was observed with the kinase inhibitor-treated HuH-7 cells transfected with HDAg expression plasmid (pECE-d or pECE-D) (Fig. 4) strongly suggests that the inhibitor did not elicit any negative effect on the production or the stability of either of the HDAgs if their expression was provided by the primary transcripts of the transfected expression vectors. Second, in the inhibitor-treated cells transfected with HDV dimeric cDNA plasmid (pSVL-d2g), the mRNA encoding large HDAg is generated through the RNA-editing process (43, 72) . In contrast, the small HDAg in these cells can be translated from the subgenomic mRNA that is transcribed from the endogenous promoter which resides within the HDV cDNA (15, 23, 44, 46, 60) . Apparently, the inhibitors did not affect the transcription directed by the endogenous promoter of HDV cDNA; if they did, the amount of small HDAg would be reduced. On the other hand, the reduction in production of the large HDAg in these inhibitor-treated cells (Fig. 3C) implies that the RNA-editing process is affected by the kinase inhibitors, presumably secondarily to the reduction of HDV replication in the treated cells (Fig. 3A and B) . These explanations would be consistent with the finding that the inhibitor did not affect the production of the two HDAgs when their expression was directed by the simian virus 40 early promoter of the pECE vector (Fig. 4) . Alternatively, these two kinases may be directly involved in the regulation of the RNA-editing process. Notably, this reduction in production of the large HDAg may partially eliminate the suppression of HDV replication exerted by the large HDAg. This may explain why only threefold inhibition of HDV genomic RNA production was detected in the CKII inhibitor-treated cells (Fig. 3) , while about sevenfold reduction in the replication activity was found in the CKII site mutant variant (S2A) of the small HDAg (Fig.  5) .
The present study also indicates that the phosphorylation properties of these two antigens are different. This is inferred from the fact that PKC can phosphorylate the small HDAg but not the large HDAg (Fig. 2) , even though the large form has an additional PKC site at Ser-210. This suggests that unlike the small HDAg, the large HDAg is folded in a structural conformation that precludes phosphorylation of potential PKC recognition sites. Thus, the conformational differences between these two HDAgs account for the differences in their phosphorylative property. The recent findings that the two forms of HDAg have different protein conformations further support this notion (27, 29) . Therefore, the tertiary structure of the HDAg is a critical determinant for substrate recognition by kinase. Specifically, this may also explain our observation that Ser-123 is the cryptic site for CKII (Fig. 6) . However, this finding does not preclude a role for phosphorylation of HDAg at these cryptic sites. Indeed, they may be unmasked in some physiological conditions and thus become targets for kinases.
The HDAg has multiple functional domains, an attribute which is relevant to their biological properties, such as oligomerization, RNA-binding ability, and nuclear transport (8, 38, 41, 42, 65, 70) . Examination of the localization of these conservative serine residues reveals that Ser-2 is located at a position adjacent to the N-terminal coiled-coil region that is important for the oligomerization of the two forms of HDAg (14, 38, 65, 70) , while Ser-123 is located within the central RNA-binding domain of HDAg (41) essential for the packaging and transactivation functions of the small HDAg (38, 41, 64) . Ser-210 is within the C-terminal 19 amino acids unique to the large HDAg. This region contains a prenylation site (18) , which is indispensable for HDV packaging (9, 28, 40) and the trans-dominant inhibitory activity of the large HDAg (29) . Since it is well-known that phosphorylation can regulate the activities of protein at multiple levels, including nuclear transport, dimerization, nucleic acid binding, and transcriptional activation (26) , phosphorylation may likewise, affect these properties of the HDAg. However, in this study we exclude the possibility that phosphorylation of these three residues modulates the nuclear transport of the HDAg (data not shown). It is possible that unphosphorylated HDAg inefficiently adopts the correct conformation, thus accounting for the low level of replication observed in the S2A mutant. An alternative mechanism is that the phosphorylation of Ser-2 causes a conformational change in the HDAg, increasing its affinity with RNA or protein to facilitate the replication. HDAg dimerization is required for its replication and trans-suppressive activity (38, 70) ; therefore, regulation of dimerization mediated by the phosphorylation could be the mechanism for regulation of HDAg function. Our preliminary results, however, argue against this because mutation at Ser-2, Ser-123, or Ser-210 does not affect the assembly of the empty viral particles or the trans-dominant activity of the large HDAg. The remaining issue of whether phosphorylation of these serines plays a role in RNA-binding ability or specificity during virion assembly is currently being investigated in our laboratory.
The present observations are of special interest in view of the current ideas concerning the possible roles of CKII and PKC in the control of nuclear activity, especially in response to cell growth factors and tumor promoter (50, 51) . Additionally, our findings allow HDAg to be added to a large list of regulatory proteins that are phosphorylated by CKII; examples include the human heat shock protein 90, simian virus 40 large T antigen, translation initiation and elongation factors, RNA polymerases I and II, DNA topoisomerases I and II, cell-cycledependent nucleolar proteins (nucleolin and nucleophosmin) and several nuclear transcriptional factors (CREB, ATF-1, and serum-responsive factor), proto-oncoproteins (c-ErbA and E1A), antioncoproteins (p53 and RB 105 ), and oncoproteins that are nuclear transcriptional regulatory factors (Myc, c-Myb, and c-Fos) (reviewed in references 48 and 63) . By utilizing a cellular protein kinase that is widely distributed in eukaryotic cells to incorporate a phosphate group in an essential HDAg, HDV probably ensures the ubiquity of its replication in the various host cells. Additionally, although in the present study we have not yet identified the crucial PKC site for HDAg function, it is likely that HDAg exhibits different properties pertinent to its biological functions through the phosphorylation or dephosphorylation of several other PKC recognition sites. Moreover, the establishment of the roles of PKC and CKII in the HDV life cycle does not rule out the possibility that other kinases may be involved in HDV replication or even assembly events. This may be the case, particularly in view of the fact that H7, the most potent inhibitor of PKC used in this study, also potently inhibits cyclic-nucleotide-dependent protein kinases to a similar extent (21) . However, our preliminary results argue against the involvement of cyclic-AMP-dependent protein kinase (PKA) because a specific inhibitor of this kinase, HA1004 (33), did not affect HDV genomic RNA replication (71) .
